The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively.

DNMT3A NPM1 acute myeloid leukemia elderly prognosis

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
29 04 2021
Historique:
received: 06 03 2021
revised: 31 03 2021
accepted: 05 04 2021
entrez: 5 5 2021
pubmed: 6 5 2021
medline: 6 5 2021
Statut: epublish

Résumé

Minimal residual disease (MRD) is now a powerful surrogate marker to assess the response to chemotherapy in acute myeloid leukemia (AML).

Identifiants

pubmed: 33947035
pii: cancers13092156
doi: 10.3390/cancers13092156
pmc: PMC8124973
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancer Cell. 2014 Apr 14;25(4):442-54
pubmed: 24656771
Leukemia. 2020 Dec;34(12):3161-3172
pubmed: 32231256
Leukemia. 2019 Nov;33(11):2741-2746
pubmed: 31209279
J Clin Oncol. 2009 Nov 20;27(33):5580-6
pubmed: 19858393
Leuk Res. 2012 Sep;36(9):1128-33
pubmed: 22749068
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Leuk Res. 2016 Jul;46:45-50
pubmed: 27123833
Nucleic Acids Res. 2019 Dec 2;47(21):11355-11367
pubmed: 31620784
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Haematologica. 2019 Jan;104(1):113-119
pubmed: 30076173
Leukemia. 2012 Jun;26(6):1247-54
pubmed: 22289988
Ann Hematol. 2017 Dec;96(12):1993-2003
pubmed: 29090343
Blood. 2001 Jan 1;97(1):89-94
pubmed: 11133746
Leukemia. 2017 Jul;31(7):1640-1644
pubmed: 28366934
Blood. 2005 Dec 1;106(12):3733-9
pubmed: 16076867
Haematologica. 2014 Aug;99(8):1317-25
pubmed: 24816240
Blood. 2013 Jul 4;122(1):83-92
pubmed: 23656730
N Engl J Med. 2010 Dec 16;363(25):2424-33
pubmed: 21067377
N Engl J Med. 2016 Feb 4;374(5):422-33
pubmed: 26789727
N Engl J Med. 2019 Oct 31;381(18):1728-1740
pubmed: 31665578
Cancers (Basel). 2019 Apr 22;11(4):
pubmed: 31013658
Blood. 2006 May 1;107(9):3481-5
pubmed: 16455952
Leukemia. 2003 Dec;17(12):2318-57
pubmed: 14562125
Blood. 2009 Sep 10;114(11):2220-31
pubmed: 19587375
Nat Med. 2016 Dec;22(12):1488-1495
pubmed: 27841873
Blood. 2020 Mar 12;135(11):870-875
pubmed: 31977039
Blood. 2010 Jan 14;115(2):198-205
pubmed: 19901261
Blood. 2010 Nov 4;116(18):3622-6
pubmed: 20656931
Leuk Res Treatment. 2013;2013:756703
pubmed: 23691328
J Clin Oncol. 2017 Jan 10;35(2):185-193
pubmed: 28056203
Blood. 2018 Mar 8;131(10):1148-1153
pubmed: 29183886
Blood Adv. 2020 May 12;4(9):1942-1949
pubmed: 32380535
Cancers (Basel). 2019 Dec 30;12(1):
pubmed: 31905904
Eur J Haematol. 2011 Nov;87(5):400-8
pubmed: 21707751
Cytogenet Genome Res. 2013;141(1):1-6
pubmed: 23817294
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Leukemia. 2006 Jun;20(6):1103-8
pubmed: 16541144
J Clin Oncol. 2011 Jul 1;29(19):2709-16
pubmed: 21555683

Auteurs

Maël Heiblig (M)

Hospices Civils de Lyon, Hematology Department, Lyon-Sud Hospital, 69310 Pierre Bénite, France.
Department of Hematology, Lyon-Sud Hospital, Bat. 1G, 165 chemin du Grand Revoyet, CEDEX, 69310 Pierre Bénite, France.

Nicolas Duployez (N)

University of Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, 59000 Lille, France.

Alice Marceau (A)

University of Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, 59000 Lille, France.

Delphine Lebon (D)

Hematology Department, CHU Amiens, 80000 Amiens, France.

Laure Goursaud (L)

Hematology Department, Center for Infection and Immunity of Lille, 59019 Lille, France.

Isabelle Plantier (I)

Hematology Department, Roubaix Hospital, 59512 Roubaix, France.

Laure Stalnikiewich (L)

Hematology Department, Lens Hospital, 62300 Lens, France.

Nathalie Cambier (N)

Hematology Department, Valenciennes Hospital, 59300 Valencienne, France.

Marie Balsat (M)

Hospices Civils de Lyon, Hematology Department, Lyon-Sud Hospital, 69310 Pierre Bénite, France.

Gaëlle Fossard (G)

Hospices Civils de Lyon, Hematology Department, Lyon-Sud Hospital, 69310 Pierre Bénite, France.

Hélène Labussière-Wallet (H)

Hospices Civils de Lyon, Hematology Department, Lyon-Sud Hospital, 69310 Pierre Bénite, France.

Fiorenza Barraco (F)

Hospices Civils de Lyon, Hematology Department, Lyon-Sud Hospital, 69310 Pierre Bénite, France.

Sophie Ducastelle-Lepretre (S)

Hospices Civils de Lyon, Hematology Department, Lyon-Sud Hospital, 69310 Pierre Bénite, France.

Pierre Sujobert (P)

Hospices Civils de Lyon, Hematology Department, Lyon-Sud Hospital, 69310 Pierre Bénite, France.

Sarah Huet (S)

Hospices Civils de Lyon, Hematology Department, Lyon-Sud Hospital, 69310 Pierre Bénite, France.

Sandrine Hayette (S)

Hospices Civils de Lyon, Hematology Department, Lyon-Sud Hospital, 69310 Pierre Bénite, France.

Hervé Ghesquières (H)

Hospices Civils de Lyon, Hematology Department, Lyon-Sud Hospital, 69310 Pierre Bénite, France.

Xavier Thomas (X)

Hospices Civils de Lyon, Hematology Department, Lyon-Sud Hospital, 69310 Pierre Bénite, France.

Claude Preudhomme (C)

University of Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, 59000 Lille, France.

Classifications MeSH